Department of Urology, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, China (mainland).
Section of Health, No. 94804 Unit of the Chinese People's Liberation Army, Shanghai, China (mainland).
Ann Transplant. 2024 Jan 2;29:e942074. doi: 10.12659/AOT.942074.
BACKGROUND Malignancy after kidney transplantation (MKT) remains a leading cause of death in transplant recipients and over the past few decades there have been many reports on this topic. However, the task of extracting crucial information from intricate events poses a significant challenge in guiding clinical work. Hence, bibliometrics was employed to summarize and predict the future in this study. MATERIAL AND METHODS Reviews and articles on MKT were extracted from the Web of Science Core Collection (WoSCC) and were analyzed by the software VOSviewer, CiteSpace, Scimago Graphica, and R package Bibliometrix for bibliometric analysis. RESULTS The analysis considered 5700 publications from 28 647 authors and 4924 institutions across 100 countries, spanning the years 1970-2022. Reference co-citation analysis showed that "renal cell carcinoma", "skin cancer", "post-transplant lymphoproliferative disorder" and "COVID-19 vaccine" were research hotspots. Keywords that co-occurred early were "immunosuppressant", "cancer", "Epstein-Barr virus", "squamous cell carcinoma", and "infection", etc., while "impact","risk factor", "outcomes", "mortality", "management" frequently co-occurred later. From 2020 to 2022, newly emerging keywords such as "SARS-CoV-2" and "COVID-19", together with citation bursts for "immune checkpoint inhibitors" and "ipilimumab," were observed. CONCLUSIONS The focus of MKT-related studies has evolved from exploring the spectrum, risk factors, and outcomes of MKT, to examining the pathogenesis, individualized screening, prevention, and treatment, including appropriate use of immune checkpoint inhibitors. Reports of renal transplant recipients infected with SARS-CoV-2 or COVID-19 have also gained attention since 2019. These suggest that individualized management remains a frontier for research and a future direction in MKT topics.
背景:肾移植后恶性肿瘤(MKT)仍然是移植受者死亡的主要原因,在过去几十年中,已经有很多关于这个主题的报道。然而,从错综复杂的事件中提取关键信息的任务在指导临床工作方面带来了巨大的挑战。因此,本研究采用文献计量学方法对其进行总结和预测。
材料和方法:从 Web of Science 核心合集(WoSCC)中提取了关于 MKT 的综述和文章,并使用 VOSviewer、CiteSpace、Scimago Graphica 和 R 包 Bibliometrix 软件进行分析。
结果:分析考虑了来自 100 个国家的 28647 名作者和 4924 个机构的 5700 篇出版物,时间跨度为 1970 年至 2022 年。参考文献共被引分析显示,“肾细胞癌”、“皮肤癌”、“移植后淋巴组织增生性疾病”和“COVID-19 疫苗”是研究热点。早期共同出现的关键词是“免疫抑制剂”、“癌症”、“Epstein-Barr 病毒”、“鳞状细胞癌”和“感染”等,而晚期共同出现的关键词是“影响”、“风险因素”、“结果”、“死亡率”和“管理”等。自 2020 年至 2022 年,观察到新出现的关键词,如“SARS-CoV-2”和“COVID-19”,以及免疫检查点抑制剂和 ipilimumab 的引文爆发。
结论:MKT 相关研究的重点已经从探讨 MKT 的谱、风险因素和结果,发展到研究发病机制、个体化筛查、预防和治疗,包括免疫检查点抑制剂的合理应用。自 2019 年以来,肾移植受者感染 SARS-CoV-2 或 COVID-19 的报道也引起了关注。这表明个体化管理仍然是研究的前沿,也是 MKT 研究的未来方向。
Transplant Proc. 2023-10
Front Public Health. 2022
Front Public Health. 2022
Front Immunol. 2022
Medicine (Baltimore). 2019-2
Vaccines (Basel). 2022-11-11
Clin J Am Soc Nephrol. 2022-3
Cancer Treat Res Commun. 2021